BTK and B-cell chronic lymphocytic leukemia: Altogether, these results reported for the first time the biological effects induced in the monocytic population of CLL patients during treatment with ibrutinib, highlighting how inhibition of BTK affects its inflammatory profile that may compromise response to fungi infection.